NR (Nicotinamide Riboside / Tru Niagen)
nik-oh-TIN-a-mide RY-boh-side
IUPAC Nicotinamide riboside
SMILES
C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)C(=O)N
C-
43.0/100
Evidence Summary
NR (Tru Niagen by ChromaDex) shares the NAD+ precursor mechanism with NMN but has a slightly stronger evidence base. ChromaDex has published more clinical trials and holds actual patents (Dartmouth-licensed). NR has FDA NDI notification with no objection.
However, like NMN, no human trial has demonstrated that raising NAD+ levels translates to improved clinical outcomes. The C- grade reflects better regulatory and source quality than NMN (D+), but the same fundamental evidence gap on human outcomes.
However, like NMN, no human trial has demonstrated that raising NAD+ levels translates to improved clinical outcomes. The C- grade reflects better regulatory and source quality than NMN (D+), but the same fundamental evidence gap on human outcomes.
Safety Considerations
Well-tolerated in clinical trials. Same theoretical cancer concern as NMN (NAD+ elevation). B12 monitoring recommended with long-term use.
Evidence Signals (0)
Known Interactions (1)
Products Containing NR (Nicotinamide Riboside / Tru Niagen)
No commercial products are currently listed for this molecule.
Regulatory Intelligence
This evidence profile reflects publicly available research as of March 15, 2026. Evidence grades may change as new research is published. ClinEvident grades the quality of published evidence — it does not evaluate the efficacy of any specific commercial product.